The paper provides an overview of current situation of the global pharmaceutical industry, with focus placed on the EU pharmaceutical market, including also the Romanian pharmaceutical market evolution synthetized into a SWOT analysis. As main goal the paper identifies several financial performance influence factors at the level of a number of companies from pharmaceutical sector, in order to g...

Pharmaceutical sales exceed $850 billion a year, of which 84% are accounted for by brand drugs. Drug prices are the focus of an ongoing heated debate. While some argue that pharmaceutical companies exploit monopolistic power granted by patent protection to set prices that are "too high", others claim that these prices are necessary to motivate the high R&D investments required in the pharmaceut...

Designing a global pricing strategy for a new pharmaceutical product has become increasingly difficult as geographic reference pricing and parallel trade have introduced global price interdependencies between different nations. What may have been an optimal pricing strategy in a single country may no longer be optimal when considering the international ramifications of this price. The prices se...

OBJECTIVES Many European countries regulate the markets for prescription drugs in order to cope with rising health expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically assessing the impact of regulation on pharmaceutical R&D expenditures. METHODS We analyze a sample of 20 leading pharmaceutical companies between 2000 a...

The question of how and when to communicate potential risks associated with new drugs has remained an important focus of tension between the pharmaceutical industry and regulatory entities, such as the American Food and Drug Administration. Recently there has been widespread concern related to the cardiovascular risks associated with the use of Avandia, a rosiglitazone produced by Glaxo Smith K...

In summary, I think the industry is doing the right things to return to profitability. Rates are increasing, underwriting and products are tightening, claim administration is becoming more proactive, and reserves are being strengthened. I think this will lead to future profitability, and future profitability will attract some new companies into the marketplace. The real long-term question is, o...

The ballistic performance of the lightweight armour systems was examined to obtain an estimate for the V50 and the global damage of the composite plates. All estimates were performed by varying the thickness of ceramic tiles, while maintaining equal areal density of the system. Simulation predictions and trial results is demonstrated both in terms of deformation and damage of the laminates and ...

In Australia, HTAs for medicines are carried out in two phases. First, a pharmaceutical company makes a submission to the Therapeutic Goods Administration, which assesses a medicine’s efficacy and safety. If the medicine is approved, an application can be made to the Pharmaceutical Benefits Advisory Committee (PBAC) to have the medicine subsidised by the Pharmaceutical Benefits Scheme (PBS). Th...

AIM To descriptively analyze the policy environment surrounding the Polish generic medicines retail market. METHOD The policy analysis was based on an international literature review. Also, a simulation exercise was carried out to compute potential savings from substituting generic for originator medicines in Poland using IMS Health pharmaceutical intelligence data. RESULTS Poland has a mat...

A set of tools that is being developed for the automated inspection of rubble-mound breakwaters, as well as its application to the survey of Sines' west breakwater armour layer, are described. The results from the IRIS surveys are compared to those of the surveys carried out by the Portuguese Hydrographic Institute and first assessment of the structure evolution between 2000 and 2003 is made.